Analyst views clinical results as central to Bavarian Nordic's external financing

Danish senior analyst Søren Løntoft Hansen views phase I/II results to be key in Bavarian Nordic's efforts to attain external financing.
Photo: Sydbank/PR
Photo: Sydbank/PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The Danish bank Sydbank sees positive aspects to Bavarian Nordic's Monday announcement that it has received a positive batch of data on the vaccine candidate ABNCovid2 against Covid-19 and will soon commence in-human studies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading